Pik K. Chan, Chao-Hsiang (Richard) Wu, Yaokai Duan, Jiu-Li Song, Chetan T. Goudar
{"title":"Automatic Assay Preparation Platform (A2P2) for Real-Time Critical Quality Attributes Monitoring of Cell Culture Samples","authors":"Pik K. Chan, Chao-Hsiang (Richard) Wu, Yaokai Duan, Jiu-Li Song, Chetan T. Goudar","doi":"10.1002/biot.70082","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>As the biopharmaceuticals industry becomes increasingly competitive, improving speed-to-market and achieving “Right First Time” are key factors that propel a company to success. Building upon our foundational work on the Automatic Assay Preparation Platform (A2P2) initially introduced to enhance process analytical technology (PAT), this publication describes its innovative application for real-time sample preparation, acquisition, and monitoring of critical quality attributes (CQAs) for biotherapeutic production. Determination of CQA in cell culture is typically supported by analytical laboratories. Titer is determined before product purification by affinity capture column using a liquid handler. Purified product concentration is then measured before subjecting to a subsequent product quality assay. This process takes up to four separate instruments and several analysts to complete. The A2P2 system, embodying an end-to-end automated and autonomous PAT solution, is configured to streamline titer measurement, product purification, purified product concentration measurement, and CQA assay within a single run sequence using a modified ultrahigh performance liquid chromatography (UHPLC<span>)</span> instrument. By utilizing Chromeleon's System Suitability Tests (SST) and Intelligence Run Control (IRC) feature and the Agilent injector program, A2P2 significantly reduces analysts’ hands-on time and shortens result turnaround time for improved efficiency. This evolution of the A2P2 system not only reduces laboratory footprint but also positions it as an ideal solution for real-time bioprocess monitoring of CQA, further advancing our commitment to accelerating the delivery of safe and effective biotherapeutics.</p>\n </div>","PeriodicalId":134,"journal":{"name":"Biotechnology Journal","volume":"20 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Journal","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/biot.70082","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
As the biopharmaceuticals industry becomes increasingly competitive, improving speed-to-market and achieving “Right First Time” are key factors that propel a company to success. Building upon our foundational work on the Automatic Assay Preparation Platform (A2P2) initially introduced to enhance process analytical technology (PAT), this publication describes its innovative application for real-time sample preparation, acquisition, and monitoring of critical quality attributes (CQAs) for biotherapeutic production. Determination of CQA in cell culture is typically supported by analytical laboratories. Titer is determined before product purification by affinity capture column using a liquid handler. Purified product concentration is then measured before subjecting to a subsequent product quality assay. This process takes up to four separate instruments and several analysts to complete. The A2P2 system, embodying an end-to-end automated and autonomous PAT solution, is configured to streamline titer measurement, product purification, purified product concentration measurement, and CQA assay within a single run sequence using a modified ultrahigh performance liquid chromatography (UHPLC) instrument. By utilizing Chromeleon's System Suitability Tests (SST) and Intelligence Run Control (IRC) feature and the Agilent injector program, A2P2 significantly reduces analysts’ hands-on time and shortens result turnaround time for improved efficiency. This evolution of the A2P2 system not only reduces laboratory footprint but also positions it as an ideal solution for real-time bioprocess monitoring of CQA, further advancing our commitment to accelerating the delivery of safe and effective biotherapeutics.
Biotechnology JournalBiochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
8.90
自引率
2.10%
发文量
123
审稿时长
1.5 months
期刊介绍:
Biotechnology Journal (2019 Journal Citation Reports: 3.543) is fully comprehensive in its scope and publishes strictly peer-reviewed papers covering novel aspects and methods in all areas of biotechnology. Some issues are devoted to a special topic, providing the latest information on the most crucial areas of research and technological advances.
In addition to these special issues, the journal welcomes unsolicited submissions for primary research articles, such as Research Articles, Rapid Communications and Biotech Methods. BTJ also welcomes proposals of Review Articles - please send in a brief outline of the article and the senior author''s CV to the editorial office.
BTJ promotes a special emphasis on:
Systems Biotechnology
Synthetic Biology and Metabolic Engineering
Nanobiotechnology and Biomaterials
Tissue engineering, Regenerative Medicine and Stem cells
Gene Editing, Gene therapy and Immunotherapy
Omics technologies
Industrial Biotechnology, Biopharmaceuticals and Biocatalysis
Bioprocess engineering and Downstream processing
Plant Biotechnology
Biosafety, Biotech Ethics, Science Communication
Methods and Advances.